@prefix this: <http://purl.org/np/RAIztrMHG-yYosqB5N47FjRMlURxJBBMUwpw6xRf8onFY> .
@prefix sub: <http://purl.org/np/RAIztrMHG-yYosqB5N47FjRMlURxJBBMUwpw6xRf8onFY#> .
@prefix drugbank: <http://identifiers.org/drugbank/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix mondo: <http://purl.obolibrary.org/obo/MONDO_> .
@prefix pav: <http://purl.org/pav/> .
@prefix infores: <https://w3id.org/biolink/infores/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix ntemplate: <https://w3id.org/np/o/ntemplate/> .
@prefix orcid: <https://orcid.org/> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix pmid: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix ncit: <http://purl.obolibrary.org/obo/NCIT_> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix biolink: <https://w3id.org/biolink/vocab/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

<http://purl.org/np/RAIztrMHG-yYosqB5N47FjRMlURxJBBMUwpw6xRf8onFY> a np:Nanopublication;
  np:hasAssertion sub:assertion;
  np:hasProvenance sub:provenance;
  np:hasPublicationInfo sub:pubInfo;
  prov:generatedAtTime "2022-09-16T11:50:48.517240"^^xsd:dateTime;
  prov:wasAttributedTo orcid:0000-0002-1501-1082;
  ntemplate:wasCreatedFromTemplate <http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY> .

drugbank:DB01267 a biolink:Drug;
  rdfs:label "Paliperidone";
  biolink:category biolink:Drug .

<http://purl.obolibrary.org/obo/MONDO_0001087> a biolink:Disease;
  rdfs:label "Schizotypal personality disorder";
  biolink:category biolink:Disease .

sub:association a biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
  rdf:object <http://purl.obolibrary.org/obo/MONDO_0001087>;
  rdf:predicate biolink:treats;
  rdf:subject drugbank:DB01267;
  rdfs:label "Similarly, De Cos Milas et al. [6] described their clinical experience with paliperidone in adolescents. They presented 3 males and 2 females, age between 15 and 17 years. Diagnoses were autism, borderline personality disorder, schizotypal personality disorder, personality disorder not otherwise specified, and schizophrenia. Prescribed dose was 3–9 mg/day, and actual mean time of treatment duration is 5.8 months. In 4 cases, paliperidone was initiated as a change from other antipsychotic. There were no adverse effects that required discontinuation and in all cases symptoms improved.";
  biolink:aggregator_knowledge_source infores:knowledge-collaboratory;
  biolink:category biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
  biolink:has_population_context sub:context;
  biolink:publications pmid:31096228;
  biolink:relation <http://purl.obolibrary.org/obo/NCIT_C94303> .

sub:context a biolink:Cohort;
  rdfs:label "Adolescents (15-17)";
  biolink:category biolink:Cohort .

sub:assertion prov:wasAttributedTo orcid:0000-0002-7641-6446 .

sub:sig npx:hasAlgorithm "RSA";
  npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCR9fz0fKCdWOWC+pxhkQhEM/ppbdIYe5TLSdj+lJzSlv9mYBaPgrzVezSwwbmhlHBPDZa4/vHycU315BdmUGq+pXllp9+rWFfrb+kBJwhZjpG6BeyyXBsRFz4jmQVxl/ZYHilQTh/XalYzKkEAyTiEMPee4Kz61PaWOKH24CsnOQIDAQAB";
  npx:hasSignature "ONZ2cjHiYvujzxAAsURK4gDhLswbE1v/AtFzeBhybK/j5B4EbFUipnx1Ix5lODeB86s8RE6aDz1PZoQuMUej1as3WP7tUgDNvI/FRtSAp9W4rsRUpNVYuEmcvy83vrHpXXavUM70b0VOCsnNSN8LqOBjM29n8cA3uZ67Q7m7FNw=";
  npx:hasSignatureTarget <http://purl.org/np/RAIztrMHG-yYosqB5N47FjRMlURxJBBMUwpw6xRf8onFY> .

<https://w3id.org/biolink/vocab/> pav:version "2.3.0" .